Sulforaphane in experimental hypertension
Background: Hypertension is defined as a failure to achieve a blood pressure (BP) target – smaller than 140/90 mmHg. The worldwide burden of hypertension has been associated with globally increased rates of death and disability. There is increasing evidence of strong relation between hypertension an...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-07-01
|
| Series: | Libyan International Medical University Journal |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/LIUJ.LIUJ_6_20 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850237550303641600 |
|---|---|
| author | Ali Banigesh Vijitha Senanayake Salma Bukhatwa Bernhard Juurlink |
| author_facet | Ali Banigesh Vijitha Senanayake Salma Bukhatwa Bernhard Juurlink |
| author_sort | Ali Banigesh |
| collection | DOAJ |
| description | Background: Hypertension is defined as a failure to achieve a blood pressure (BP) target – smaller than 140/90 mmHg. The worldwide burden of hypertension has been associated with globally increased rates of death and disability. There is increasing evidence of strong relation between hypertension and oxidative stress, where either increased oxidative stress or depressed antioxidant level may lead to hypertension. Using stroke-prone spontaneously hypertensive rats (SHRSP) rats, previous studies in our laboratory have shown that broccoli sprouts (high in sulforaphane, a phase-2 protein inducer) attenuate BP and inflammation. Objectives: The question this study addressed was whether sulforaphane (a potent phase-2 protein inducer) can attenuate hypertension in the experimental model using the stroke-prone spontaneously hypertensive rats (SHRsp). Materials and Methods: Sulforaphane (LKT Laboratories) or vehicle was orally gavaged to SHRsp or Sprague–Dawley rats (SD) daily for 15 weeks. The body weight and BP were determined weekly, using a standard tail-cuff BP measurement. Tissues such as hearts and kidneys were collected, weighed, and stored under −80°C for further analysis. Results: When compared to BP in SHRsp control rats (179.9 ± 4.32), sulforaphane significantly reduced BP to 157 ± 5.21 (10 μmol/kg body weight), 136.57 ± 1.96 (20 μmol/kg body weight), and 129.33 ± 6.10 (5 μmol/kg body weight), respectively, in SHRsp rats. Conclusion: Administration of sulforaphane, a potent phase-2 enzyme inducer, daily for more than 3 months, significantly improves BP in SHRsp rats, but it did not have any effects on normotensive rats – SD. |
| format | Article |
| id | doaj-art-2c2cc68005394fe4bc46b6d6ca66eb66 |
| institution | OA Journals |
| issn | 2519-139X |
| language | English |
| publishDate | 2020-07-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Libyan International Medical University Journal |
| spelling | doaj-art-2c2cc68005394fe4bc46b6d6ca66eb662025-08-20T02:01:42ZengThieme Medical and Scientific Publishers Pvt. Ltd.Libyan International Medical University Journal2519-139X2020-07-010502273110.4103/LIUJ.LIUJ_6_20Sulforaphane in experimental hypertensionAli Banigesh0Vijitha Senanayake1Salma Bukhatwa2Bernhard Juurlink3Department of Pharmacology and Toxicology, College of Pharmacy, University of Benghazi, Benghazi, LibyaDepartment of Anatomy and Cell Biology, College of Medicine, University of Saskatchewan, Saskatoon, CanadaDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Benghazi, Benghazi, LibyaDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Benghazi, Benghazi, LibyaBackground: Hypertension is defined as a failure to achieve a blood pressure (BP) target – smaller than 140/90 mmHg. The worldwide burden of hypertension has been associated with globally increased rates of death and disability. There is increasing evidence of strong relation between hypertension and oxidative stress, where either increased oxidative stress or depressed antioxidant level may lead to hypertension. Using stroke-prone spontaneously hypertensive rats (SHRSP) rats, previous studies in our laboratory have shown that broccoli sprouts (high in sulforaphane, a phase-2 protein inducer) attenuate BP and inflammation. Objectives: The question this study addressed was whether sulforaphane (a potent phase-2 protein inducer) can attenuate hypertension in the experimental model using the stroke-prone spontaneously hypertensive rats (SHRsp). Materials and Methods: Sulforaphane (LKT Laboratories) or vehicle was orally gavaged to SHRsp or Sprague–Dawley rats (SD) daily for 15 weeks. The body weight and BP were determined weekly, using a standard tail-cuff BP measurement. Tissues such as hearts and kidneys were collected, weighed, and stored under −80°C for further analysis. Results: When compared to BP in SHRsp control rats (179.9 ± 4.32), sulforaphane significantly reduced BP to 157 ± 5.21 (10 μmol/kg body weight), 136.57 ± 1.96 (20 μmol/kg body weight), and 129.33 ± 6.10 (5 μmol/kg body weight), respectively, in SHRsp rats. Conclusion: Administration of sulforaphane, a potent phase-2 enzyme inducer, daily for more than 3 months, significantly improves BP in SHRsp rats, but it did not have any effects on normotensive rats – SD.http://www.thieme-connect.de/DOI/DOI?10.4103/LIUJ.LIUJ_6_20blood pressurehypertensionshrspsprague–dawleysulforaphane |
| spellingShingle | Ali Banigesh Vijitha Senanayake Salma Bukhatwa Bernhard Juurlink Sulforaphane in experimental hypertension Libyan International Medical University Journal blood pressure hypertension shrsp sprague–dawley sulforaphane |
| title | Sulforaphane in experimental hypertension |
| title_full | Sulforaphane in experimental hypertension |
| title_fullStr | Sulforaphane in experimental hypertension |
| title_full_unstemmed | Sulforaphane in experimental hypertension |
| title_short | Sulforaphane in experimental hypertension |
| title_sort | sulforaphane in experimental hypertension |
| topic | blood pressure hypertension shrsp sprague–dawley sulforaphane |
| url | http://www.thieme-connect.de/DOI/DOI?10.4103/LIUJ.LIUJ_6_20 |
| work_keys_str_mv | AT alibanigesh sulforaphaneinexperimentalhypertension AT vijithasenanayake sulforaphaneinexperimentalhypertension AT salmabukhatwa sulforaphaneinexperimentalhypertension AT bernhardjuurlink sulforaphaneinexperimentalhypertension |